{"id":"glucocerebrosidase","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"28.4%","placeboRate":"","totalAtRisk":95,"totalAffected":27,"trialsReporting":3},{"effect":"Arthralgia","drugRate":"22.1%","placeboRate":"","totalAtRisk":95,"totalAffected":21,"trialsReporting":3},{"effect":"Headache","drugRate":"22.1%","placeboRate":"","totalAtRisk":95,"totalAffected":21,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"14.7%","placeboRate":"","totalAtRisk":95,"totalAffected":14,"trialsReporting":3},{"effect":"Back pain","drugRate":"13.7%","placeboRate":"","totalAtRisk":95,"totalAffected":13,"trialsReporting":3},{"effect":"Cough","drugRate":"13.7%","placeboRate":"","totalAtRisk":95,"totalAffected":13,"trialsReporting":3},{"effect":"Fatigue","drugRate":"12.6%","placeboRate":"","totalAtRisk":95,"totalAffected":12,"trialsReporting":3},{"effect":"Pharyngolaryngeal pain","drugRate":"12.6%","placeboRate":"","totalAtRisk":95,"totalAffected":12,"trialsReporting":3},{"effect":"Pyrexia","drugRate":"11.6%","placeboRate":"","totalAtRisk":95,"totalAffected":11,"trialsReporting":3},{"effect":"Influenza","drugRate":"11.6%","placeboRate":"","totalAtRisk":95,"totalAffected":11,"trialsReporting":3},{"effect":"Myalgia","drugRate":"10.5%","placeboRate":"","totalAtRisk":95,"totalAffected":10,"trialsReporting":3},{"effect":"Pain in extremity","drugRate":"10.5%","placeboRate":"","totalAtRisk":95,"totalAffected":10,"trialsReporting":3},{"effect":"Abdominal pain upper","drugRate":"9.5%","placeboRate":"","totalAtRisk":95,"totalAffected":9,"trialsReporting":3},{"effect":"Diarrhoea","drugRate":"9.5%","placeboRate":"","totalAtRisk":95,"totalAffected":9,"trialsReporting":3},{"effect":"Bone pain","drugRate":"16.4%","placeboRate":"","totalAtRisk":55,"totalAffected":9,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"8.4%","placeboRate":"","totalAtRisk":95,"totalAffected":8,"trialsReporting":3},{"effect":"Hypertension","drugRate":"8.4%","placeboRate":"","totalAtRisk":95,"totalAffected":8,"trialsReporting":3},{"effect":"Pharyngitis","drugRate":"9.0%","placeboRate":"","totalAtRisk":78,"totalAffected":7,"trialsReporting":2},{"effect":"Paraesthesia","drugRate":"7.4%","placeboRate":"","totalAtRisk":95,"totalAffected":7,"trialsReporting":3},{"effect":"Influenza like illness","drugRate":"6.3%","placeboRate":"","totalAtRisk":95,"totalAffected":6,"trialsReporting":3},{"effect":"Epistaxis","drugRate":"6.3%","placeboRate":"","totalAtRisk":95,"totalAffected":6,"trialsReporting":3},{"effect":"Toothache","drugRate":"5.3%","placeboRate":"","totalAtRisk":95,"totalAffected":5,"trialsReporting":3},{"effect":"Bronchitis","drugRate":"5.3%","placeboRate":"","totalAtRisk":95,"totalAffected":5,"trialsReporting":3},{"effect":"Vomiting","drugRate":"5.3%","placeboRate":"","totalAtRisk":95,"totalAffected":5,"trialsReporting":3},{"effect":"Sinus congestion","drugRate":"6.4%","placeboRate":"","totalAtRisk":78,"totalAffected":5,"trialsReporting":2},{"effect":"Procedural pain","drugRate":"6.4%","placeboRate":"","totalAtRisk":78,"totalAffected":5,"trialsReporting":2},{"effect":"Nausea","drugRate":"8.8%","placeboRate":"","totalAtRisk":57,"totalAffected":5,"trialsReporting":2},{"effect":"Sinusitis","drugRate":"7.3%","placeboRate":"","totalAtRisk":55,"totalAffected":4,"trialsReporting":2},{"effect":"Dizziness","drugRate":"4.2%","placeboRate":"","totalAtRisk":95,"totalAffected":4,"trialsReporting":3},{"effect":"Abdominal pain","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Gastroenteritis","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Shoulder pain","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Rhinitis","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Vaginal infection","drugRate":"7.9%","placeboRate":"","totalAtRisk":38,"totalAffected":3,"trialsReporting":1},{"effect":"Muscle spasms","drugRate":"3.2%","placeboRate":"","totalAtRisk":95,"totalAffected":3,"trialsReporting":3},{"effect":"Osteoarthritis","drugRate":"7.9%","placeboRate":"","totalAtRisk":38,"totalAffected":3,"trialsReporting":1},{"effect":"Dermatitis allergic","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Dry eye","drugRate":"5.5%","placeboRate":"","totalAtRisk":55,"totalAffected":3,"trialsReporting":2},{"effect":"Activated partial thromboplastin time prolonged","drugRate":"5.3%","placeboRate":"","totalAtRisk":57,"totalAffected":3,"trialsReporting":2},{"effect":"Blood glucose increased","drugRate":"7.5%","placeboRate":"","totalAtRisk":40,"totalAffected":3,"trialsReporting":1},{"effect":"Nasal congestion","drugRate":"7.5%","placeboRate":"","totalAtRisk":40,"totalAffected":3,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"5.3%","placeboRate":"","totalAtRisk":57,"totalAffected":3,"trialsReporting":2},{"effect":"Ear pain","drugRate":"7.5%","placeboRate":"","totalAtRisk":40,"totalAffected":3,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"17.6%","placeboRate":"","totalAtRisk":17,"totalAffected":3,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"5.3%","placeboRate":"","totalAtRisk":38,"totalAffected":2,"trialsReporting":1},{"effect":"Tinea versicolour","drugRate":"3.6%","placeboRate":"","totalAtRisk":55,"totalAffected":2,"trialsReporting":2},{"effect":"Tonsillitis","drugRate":"3.6%","placeboRate":"","totalAtRisk":55,"totalAffected":2,"trialsReporting":2},{"effect":"Adverse drug reaction","drugRate":"5.3%","placeboRate":"","totalAtRisk":38,"totalAffected":2,"trialsReporting":1},{"effect":"Diarrhoea infectious","drugRate":"5.3%","placeboRate":"","totalAtRisk":38,"totalAffected":2,"trialsReporting":1},{"effect":"Vulvovaginal mycotic infection","drugRate":"5.3%","placeboRate":"","totalAtRisk":38,"totalAffected":2,"trialsReporting":1}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1201633","moleculeType":"Enzyme"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T02:38:40.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:50:58.062336+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic non-neuropathic Gaucher's disease","diseaseId":"chronic-non-neuropathic-gaucher's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00001215","phase":"","title":"Genetic Studies of Lysosomal Storage Disorders","status":"ENROLLING_BY_INVITATION","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"1995-03-08","conditions":"Lysosomal Storage Disorders, Gaucher Disease, Parkinson Disease","enrollment":1000},{"nctId":"NCT04370665","phase":"NA","title":"Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease","status":"COMPLETED","sponsor":"InSightec","startDate":"2020-07-16","conditions":"Parkinson Disease","enrollment":4},{"nctId":"NCT04127578","phase":"PHASE1, PHASE2","title":"Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-01-03","conditions":"Parkinson Disease","enrollment":32},{"nctId":"NCT00302146","phase":"","title":"Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2006-05-23","conditions":"Parkinson Disease, Gaucher Disease","enrollment":64},{"nctId":"NCT05565443","phase":"NA","title":"MR-guided Focused Ultrasound Plus GCase","status":"RECRUITING","sponsor":"InSightec","startDate":"2022-11-30","conditions":"Parkinsons Disease","enrollment":14},{"nctId":"NCT03485677","phase":"PHASE3","title":"Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-04-11","conditions":"Gaucher's Disease Type I, Gaucher's Disease Type III","enrollment":57},{"nctId":"NCT00358943","phase":"","title":"International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"1991-04-01","conditions":"Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease","enrollment":12000},{"nctId":"NCT04228172","phase":"","title":"Genotypic Influences on Network Progression in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2020-02-24","conditions":"Parkinson's Disease","enrollment":32},{"nctId":"NCT04411654","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2021-06-29","conditions":"Gaucher Disease, Type 2","enrollment":7},{"nctId":"NCT05819359","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bial R&D Investments, S.A.","startDate":"2023-03-31","conditions":"Parkinson's Disease","enrollment":237},{"nctId":"NCT05304195","phase":"","title":"Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-17","conditions":"Dementia With Lewy Bodies","enrollment":236},{"nctId":"NCT05222906","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-04-18","conditions":"Gaucher's Disease Type III","enrollment":43},{"nctId":"NCT05518617","phase":"","title":"Molecular and Functional Imaging in Monogenic PD.","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2022-07-01","conditions":"Parkinson Disease, Nervous System Disorder, Neurodegenerative Diseases","enrollment":45},{"nctId":"NCT04656600","phase":"PHASE4","title":"Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-03-02","conditions":"Gaucher's Disease","enrollment":12},{"nctId":"NCT05287503","phase":"PHASE2","title":"Ambroxol as a Disease-modifying Treatment in GBA-PD","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2022-03-09","conditions":"Parkinson Disease, GBA Gene Mutation","enrollment":65},{"nctId":"NCT07055087","phase":"PHASE2","title":"Prevent Cognitive Decline in GBA-associated Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-12","conditions":"Parkinson's Disease","enrollment":120},{"nctId":"NCT05529992","phase":"PHASE3","title":"A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-03","conditions":"Gaucher Disease","enrollment":20},{"nctId":"NCT04101968","phase":"","title":"The GBA Multimodal Study in Parkinson's Disease","status":"RECRUITING","sponsor":"Pacific Parkinson's Research Centre","startDate":"2019-05-01","conditions":"Parkinson Disease, GBA Gene Mutation, Gaucher Disease","enrollment":25},{"nctId":"NCT06869499","phase":"NA","title":"Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2025-05","conditions":"Splenomegaly, Splenectomy, Thrombopenia","enrollment":200},{"nctId":"NCT02843035","phase":"PHASE2","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-01-04","conditions":"Gaucher Disease Type 1, Gaucher Disease Type 3","enrollment":12},{"nctId":"NCT05536388","phase":"","title":"Drug Discovery for Parkinson's With Mutations in the GBA Gene","status":"RECRUITING","sponsor":"New York Stem Cell Foundation Research Institute","startDate":"2022-07-15","conditions":"Parkinson Disease, Gaucher Disease, Healthy","enrollment":60},{"nctId":"NCT06814431","phase":"","title":"Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2023-11-23","conditions":"Idiopathic Parkinson's Disease (PD)","enrollment":3000},{"nctId":"NCT06451419","phase":"","title":"Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Juan Pablo Romero. MD, PhD","startDate":"2024-07-01","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT06323278","phase":"","title":"Effectiveness of Cognitive Stimulation Treatment in Patients With Parkinson's Disease","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2021-12-21","conditions":"Parkinson Disease","enrollment":68},{"nctId":"NCT06193421","phase":"PHASE1, PHASE2","title":"High-Dose Ambroxol in GBA1-Related Parkinson","status":"UNKNOWN","sponsor":"Agyany Pharma LTD","startDate":"2023-10-24","conditions":"Parkinson Disease, GBA Gene Mutation","enrollment":40},{"nctId":"NCT06167603","phase":"","title":"Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-04-30","conditions":"Parkinson Disease","enrollment":140},{"nctId":"NCT04145037","phase":"PHASE1, PHASE2","title":"Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease","status":"TERMINATED","sponsor":"AVROBIO","startDate":"2019-05-30","conditions":"Gaucher Disease","enrollment":8},{"nctId":"NCT05815004","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3","status":"WITHDRAWN","sponsor":"AVROBIO","startDate":"2023-10","conditions":"Gaucher Disease, Type 3","enrollment":""},{"nctId":"NCT04120506","phase":"PHASE4","title":"Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2016-01-10","conditions":"Gaucher Disease, Type 1","enrollment":15},{"nctId":"NCT03519646","phase":"NA","title":"Eliglustat on Gaucher Disease Type IIIB","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-04-23","conditions":"Gaucher Disease, Type III","enrollment":4},{"nctId":"NCT02906020","phase":"PHASE2","title":"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2016-12-15","conditions":"Parkinson's Disease","enrollment":273},{"nctId":"NCT02574286","phase":"PHASE4","title":"Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2016-06-29","conditions":"Gaucher Disease","enrollment":21},{"nctId":"NCT04268030","phase":"","title":"High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2020-02-11","conditions":"Parkinson Disease","enrollment":9},{"nctId":"NCT00430625","phase":"PHASE3","title":"A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2007-02-15","conditions":"Gaucher Disease, Type 1","enrollment":25},{"nctId":"NCT01614574","phase":"PHASE3","title":"Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-02","conditions":"Gaucher Disease","enrollment":6},{"nctId":"NCT00391625","phase":"PHASE1, PHASE2","title":"Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)","status":"COMPLETED","sponsor":"Shire","startDate":"2004-09-13","conditions":"Gaucher Disease","enrollment":10},{"nctId":"NCT01842841","phase":"PHASE3","title":"Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2013-03-13","conditions":"Gaucher Disease","enrollment":5},{"nctId":"NCT01685216","phase":"PHASE1, PHASE2","title":"Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2012-09-14","conditions":"Gaucher Disease, Type 3","enrollment":7},{"nctId":"NCT00635427","phase":"PHASE3","title":"An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-03-13","conditions":"Gaucher Disease, Type 1","enrollment":95},{"nctId":"NCT00478647","phase":"PHASE2, PHASE3","title":"Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase","status":"COMPLETED","sponsor":"Shire","startDate":"2007-07-25","conditions":"Gaucher Disease","enrollment":40},{"nctId":"NCT00553631","phase":"PHASE3","title":"Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-01-29","conditions":"Gaucher Disease, Type 1","enrollment":34},{"nctId":"NCT00954460","phase":"","title":"Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Shire","startDate":"","conditions":"Gaucher Disease, Type 1","enrollment":""},{"nctId":"NCT04787887","phase":"PHASE1","title":"A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2020-01-29","conditions":"Gaucher Disease","enrollment":42},{"nctId":"NCT03702361","phase":"PHASE4","title":"Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2018-09-04","conditions":"Primary Disease","enrollment":15},{"nctId":"NCT00923169","phase":"PHASE1","title":"Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-07-09","conditions":"Renal Cell Carcinoma","enrollment":9},{"nctId":"NCT03811496","phase":"","title":"Biomarker Analysis for GBA Associated Parkinson's Disease","status":"UNKNOWN","sponsor":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","startDate":"2018-02-01","conditions":"Parkinson Disease, Gaucher Disease","enrollment":100},{"nctId":"NCT01132690","phase":"PHASE4","title":"A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Gaucher Disease","enrollment":11},{"nctId":"NCT00705939","phase":"PHASE3","title":"Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Gaucher Disease","enrollment":45},{"nctId":"NCT00712348","phase":"PHASE3","title":"Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Gaucher Disease","enrollment":31},{"nctId":"NCT00376168","phase":"PHASE3","title":"A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-08","conditions":"Gaucher Disease","enrollment":32},{"nctId":"NCT00962260","phase":"","title":"Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Gaucher Disease","enrollment":""},{"nctId":"NCT01411228","phase":"PHASE3","title":"A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Gaucher Disease","enrollment":15},{"nctId":"NCT02528617","phase":"PHASE4","title":"The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2015-07","conditions":"Gaucher Disease Type 1, Gaucher Disease Type 3","enrollment":""},{"nctId":"NCT02770625","phase":"PHASE3","title":"Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-09","conditions":"Gaucher Disease, Type 1","enrollment":8},{"nctId":"NCT00244582","phase":"","title":"Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2005-10-22","conditions":"Type 2 Gaucher Disease","enrollment":1},{"nctId":"NCT00001289","phase":"","title":"Effects of Enzyme Replacement in Gaucher's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1991-09-23","conditions":"Gaucher's Disease","enrollment":70},{"nctId":"NCT00891202","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-11","conditions":"Gaucher Disease, Type 1","enrollment":40},{"nctId":"NCT00358150","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-06","conditions":"Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease","enrollment":26},{"nctId":"NCT01074944","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-06","conditions":"Gaucher Disease","enrollment":170},{"nctId":"NCT00943111","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-09","conditions":"Gaucher Disease, Type 1","enrollment":160},{"nctId":"NCT01344096","phase":"","title":"Thrombocytopathy in Gaucher Disease Patients","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2010-10","conditions":"Gaucher Disease, Thrombocytopathy","enrollment":70},{"nctId":"NCT02107846","phase":"PHASE2","title":"An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112","status":"COMPLETED","sponsor":"Protalix","startDate":"2014-04","conditions":"Gaucher Disease","enrollment":10},{"nctId":"NCT00001416","phase":"PHASE2","title":"Bone Response to Enzyme Replacement in Gaucher's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1993-12","conditions":"Gaucher's Disease","enrollment":100},{"nctId":"NCT01161914","phase":"PHASE3","title":"The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease","status":"WITHDRAWN","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-01","conditions":"Gaucher Disease","enrollment":""},{"nctId":"NCT01136304","phase":"","title":"Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)","status":"COMPLETED","sponsor":"University Research Foundation for Lysosomal Storage Diseases, Inc.","startDate":"2010-04","conditions":"Gaucher Disease","enrollment":173},{"nctId":"NCT00364858","phase":"PHASE4","title":"Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-12","conditions":"Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease","enrollment":95},{"nctId":"NCT00365131","phase":"PHASE4","title":"A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"1997-12","conditions":"Gaucher Disease Type I, Cerebroside Lipidosis Syndrome, Clucocerebrosidase Deficiency Disease","enrollment":40},{"nctId":"NCT01747980","phase":"PHASE1","title":"Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients","status":"COMPLETED","sponsor":"Protalix","startDate":"2013-03","conditions":"Gaucher Disease","enrollment":16},{"nctId":"NCT02053896","phase":"","title":"A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-05","conditions":"Gaucher Disease","enrollment":5},{"nctId":"NCT01951989","phase":"PHASE2","title":"Intra-monocyte Imiglucerase Kinetics in Gaucher Disease","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2012-11","conditions":"Gaucher Disease","enrollment":60},{"nctId":"NCT01881633","phase":"PHASE1","title":"A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2010-10","conditions":"Gaucher Disease","enrollment":24},{"nctId":"NCT01716741","phase":"NA","title":"Identification of Undiagnosed Gaucher Disease","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2012-08","conditions":"Gaucher Disease","enrollment":100},{"nctId":"NCT01089283","phase":"","title":"Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2010-03","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT00001410","phase":"PHASE1","title":"PEG-Glucocerebrosidase for the Treatment of Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1993-10","conditions":"Gaucher's Disease","enrollment":18},{"nctId":"NCT00001234","phase":"PHASE1","title":"Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1988-01","conditions":"Gaucher's Disease","enrollment":120},{"nctId":"NCT00258778","phase":"PHASE1","title":"Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)","status":"COMPLETED","sponsor":"Protalix","startDate":"2005-11","conditions":"Gaucher Disease","enrollment":6},{"nctId":"NCT00004293","phase":"PHASE2","title":"Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-11","conditions":"Gaucher's Disease","enrollment":24},{"nctId":"NCT00004294","phase":"PHASE1","title":"Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-11","conditions":"Gaucher's Disease","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":1,"reaction":"PARAINFLUENZAE VIRUS INFECTION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2831,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"glucocerebrosidase","genericName":"glucocerebrosidase","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":8,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:50:58.062336+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}